Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026
Cadrenal Therapeutics plans to initiate a Phase 2a proof-of-concept trial of its lead asset CAD-1005 to prevent Acute Kidney Injury (AKI) in high-risk cardiac surgery patients. The trial targets Cardiac Surgery-Associated AKI (CSA-AKI), a condition affecting 35,000 U.S. patients annually with no approved targeted therapies, representing a $1 billion market.
Key figures
- Drug Name
- CAD-1005
- Phase Of Trial
- Phase 2a
- Csa aki market size usd
- $1 billion
- Hospital mortality increase
- 8-fold
- Csa aki us patients annually
- 35000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.